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The recent development of infectious retroviral pseudotypes bearing hepatitis C virus (HCV) glycoproteins
represents an opportunity to study the functionally active form of the HCV E1 and E2 glycoproteins. In the
culture supernatant of cells producing HCV retroviral pseudotypes, the majority of E2 was not associated with
infectious particles and failed to sediment on sucrose gradients. The E2 that was incorporated into infectious
particles appeared as a triplet of diffuse bands at 60, 70, and 90 kDa. Similarly, three major forms of E1 were
incorporated into the pseudotype particles, migrating at 33, 31, and 25 kDa. Endoglycosidase H (endo-H)
treatment of particles demonstrated that the incorporated E1 was partially or completely sensitive to digestion.
In contrast, the majority of the incorporated E2 was endo-H resistant. Purified pseudotype particles were found
to contain both disulfide-linked aggregates and nonaggregated E1 and E2. HCV pseudotypes generated from
cells expressing E1E2p7 showed similar heterogeneity in the incorporated glycoproteins and were of compa-
rable infectivity to those generated by expression of E1E2. Our results demonstrate the heterogenous nature
of E1 and E2 incorporated into retroviral pseudotypes and highlight the difficulty in identifying forms of the
HCV glycoproteins that initiate infection.
Hepatitis C virus (HCV) is an enveloped virus classified in
the Hepacivirus genus of the family Flaviviridae (22). The sin-
gle-stranded, positive-sense RNA genome contains a single
open reading frame that is translated to yield the viral proteins
in the form of a polyprotein. A cellular signal peptidase re-
leases the putative structural proteins (core, E1, E2, and p7)
from this polyprotein, consistent with their translocation across
the endoplasmic reticulum (ER) membrane. E1 and E2 are
type I integral transmembrane proteins that undergo extensive
N-linked glycosylation and are likely to function in virus at-
tachment and cell entry. The p7 protein is a 63-amino-acid
hydrophobic polypeptide predicted to contain two transmem-
brane-spanning regions and localized to both the plasma mem-
brane and ER of expressing cells (3). Cleavage at the E2-p7
junction is inefficient, resulting in the production of an E2-p7
species of unknown function (21, 24). While dispensable for
the replication of HCV subgenomic replicons, p7 is critical for
infectivity in the chimpanzee (32) and has recently been shown
to function as an ion channel (18, 28).
Due to the lack of an in vitro system that efficiently supports
the full virus life cycle, most studies of the HCV structural
proteins have used heterologous expression systems (reviewed
in references 11 and 27). Both E1 and E2 glycoproteins (gp’s)
have been reported to localize to the ER, with no cell surface
expression detectable. The glycans associated with these pro-
teins are not modified by Golgi enzymes and are sensitive to
endoglycosidase H (endo-H), suggesting static retention of E1
and E2 in an early compartment of the secretory pathway (15).
These observations are consistent with a model of HCV as-
sembly at the ER membrane and are supported by the pres-
ence of ER retention signals within the transmembrane do-
mains of both gp’s (5, 7, 17, 25).
Expression studies in vitro have revealed two forms of the
gp’s: aggregates covalently linked by disulfide bonds, and non-
covalently associated E1E2 heterodimers. Aggregated gp’s
have been suggested to result from a nonproductive folding
pathway, whereas noncovalently associated heterodimers may
represent a prebudding form of the gp’s (9, 12, 13). Currently,
there is little information on the disulfide bonding and glyco-
sylation status of E1 and E2 in native HCV particles. In hep-
atoma cells supporting full-length HCV RNA replication, only
noncovalently associated E1E2 was observed, whereas tran-
sient plasmid-based expression of the same proteins resulted in
the formation of disulfide-linked aggregates (reference 30 and
unpublished observations).
Our laboratory (19) and others (2, 10) recently reported
HCV gp expression at the surface of transiently transfected
cells, allowing the genesis of retroviral particles bearing the
HCV gp’s. These pseudotype particles are infectious for liver-
derived cells and represent a tool to study a functional HCV gp
complex. To identify the functional form of the HCV gp’s, we
characterized the E1 and E2 incorporated into infectious
pseudotype particles. The incorporated gp’s were found to be
heterogeneous with respect to their molecular mass, disulfide
linkages, and glycosylation.
MATERIALS AND METHODS
Antibodies and reagents. Rat monoclonal antibodies (MAbs) 10/76b, 11/20,
3/11, 6/53, 7/16, and 6/1a were previously described (16). Anti-E1 MAb 725P was
purchased from Maine Biotechnology (Portland, Maine), A4 was a kind gift from
H. Greenberg (Stanford University, Stanford, Calif.), and H52 and H53 were
from Jean Dubuisson (Institut Pasteur de Lille, Lille, France). Immunoblot
assays for E1 were performed with a mixture of A4 and 725P and for E2 with a
mixture of 3/11, 6/53, and 6/1a. Horseradish peroxidase-conjugated anti-mouse
(Pierce, Rockford, Ill.) and anti-rat (Jackson, West Grove, Pa.) immunoglobulin
G were used according to the manufacturers’ recommendations. Endo-H and
N-glycosidase F were used according to the manufacturer’s instructions (Calbio-
* Corresponding author. Mailing address: The Center for the Study
of Hepatitis C, The Rockefeller University, Box 64, 1230 York Ave.,
New York, NY 10021. Phone: (212) 327-7066. Fax: (212) 327-7047.
E-mail: mckeatj@mail.rockefeller.edu.
6875
chem, San Diego, Calif.). Dulbecco’s modified Eagle medium (DMEM) and fetal
bovine serum (FBS) were from Invitrogen (Carlsbad, Calif.). Plasmid
pNL4.3.Luc.RE (8) was obtained through the AIDS Research and Reference
Reagent Program, Division of AIDS, National Institute of Allergy and Infectious
Diseases, National Institutes of Health.
Plasmid construction. Sequences encoding E1E2 (polyprotein residues 170 to
746) and E1E2p7 (residues 170 to 809) of the H77 HCV sequence were amplified
by PCR and ligated with pcDNA3.1(-)neo (Invitrogen) using standard proce-
dures. Inserts were sequenced to confirm identity. The endogenous signal se-
quence constituting the 21 most-C-terminal amino acid residues of Core were
included to allow translocation across the ER membrane. Expression vectors
encoding Core-E1E2p7 (polyprotein residues 1 to 809), E1E2p7NS2 (residues
170 to 1026), and Core-E1E2p7NS2 (residues 1 to 1026) were generated simi-
larly.
Generation of HIV-HCV pseudotype particles. Human immunodeficiency vi-
rus (HIV)-HCV pseudotypes were generated as previously described (19).
Briefly, 293T cells were cotransfected with an E1E2 expression plasmid and
pNL4.3.Luc.RE, using Lipofectamine 2000 (Invitrogen). Lipid-DNA com-
plexes were removed 4 to 6 h later and replaced with DMEM supplemented with
3% FBS. At 48 h posttransfection, the culture medium was collected, clarified by
low-speed centrifugation for 15 min, and then stored at 4°C before analysis.
Transfected cell monolayers were washed with phosphate-buffered saline (PBS)
and resuspended in lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1%
NP-40, Complete protease inhibitors [Roche Biochemicals, Indianapolis, Ind.])
on ice for 30 min. Lysates were clarified by centrifugation at 4°C for 15 min at
maximum speed in a microcentrifuge, and the resulting supernatants were re-
moved, aliquoted, and stored frozen at 80°C.
Infectivity assay. Retroviral pseudotype infectivity was measured as previously
described (19). Briefly, Hep3B cells were seeded at 8  103 cells per well of a
96-well plate the day prior to infection. For infection, medium was removed and
pseudotype virus stock, diluted in DMEM supplemented with 3% FBS and 4 g
of Polybrene (Sigma, St. Louis, Mo.)/ml, was added. After overnight incubation,
the inoculum was removed and replaced with DMEM supplemented with 3%
FBS. At 72 h postinfection, the medium was removed and the cells were lysed
with 40 l of cell lysis buffer (Promega, Madison, Wis.) per well. Luciferase
activity was assayed by the addition of 35 l of lysate to 50 l of luciferase
substrate and measured for 10 s in a luminometer (Lumat LB 9507).
Sucrose gradients. Linear sucrose gradients were formed on a Gradient Mas-
ter 107ip (Biocomp Inc., New Brunswick, Canada) according to the manufactur-
er’s instructions. For analysis of sedimentation, 7-to-47% (wt/vol, in PBS) su-
crose gradients were centrifuged in an SW41 rotor at 35,000 rpm for 3 h at 4°C.
Fractions were collected from the top of the gradient and trichloroacetic acid
(TCA) precipitated prior to separation by sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis (SDS-PAGE). Since the sucrose concentration in frac-
tions from a 7-to-47% gradient was inhibitory in the Hep3B infectivity assay,
linear 5-to-20% (wt/vol, in PBS) sucrose gradients were used for infectivity
studies. These gradients were centrifuged in an SW41 rotor for 15 min at 35,000
rpm at 4°C. For pelleting virus through a sucrose cushion, 10 ml of cell culture
medium was layered onto 1.5 ml of 20% (wt/vol, in PBS) sucrose before centrif-
ugation at 25,000 rpm in an SW41 rotor for 3.5 h. The medium and cushion were
discarded, and the virus pellet was resuspended in 100 l of PBS on ice.
p24 ELISA. After pelleting through a sucrose cushion, the pseudotype virus
was inactivated by resuspension in PBS supplemented with 1% Empigen and
incubated at 56°C for 30 min. A commercially available HIV type 1 p24 antigen
enzyme-linked immunosorbent assay (ELISA) protocol (Aalto Bio Reagents,
Dublin, Ireland) was used to quantify the p24 content of samples.
RESULTS
The majority of extracellular E2 is not associated with in-
fectious particles. Due to the lack of an efficient cell culture
system to propagate HCV, the nature of functional HCV E1E2
gp’s is unclear. The recent observation that retroviruses can
incorporate HCV gp’s, and that the resulting viruses infect
human liver-derived cells in a pH-dependent manner, suggests
that these particles contain functional HCV gp’s (2, 19, 34).
We therefore isolated HIV-HCV particles and characterized
their incorporated E1 and E2.
The clarified cell culture medium from transfected 293T
cells producing HIV-HCV pseudotype particles was analyzed
by velocity sedimentation on a 5-to-20% sucrose gradient.
Fractions were collected and analyzed by immunoblotting for
HCV E2 and p24, the HIV type 1 capsid protein (Fig. 1A).
Surprisingly, the majority of E2 did not sediment, remaining in
FIG. 1. The majority of released E2 does not cosediment with parti-
cles or infectivity. Cell culture medium from 293T cells producing HIV-
HCV pseudotype particles was applied to a 5-to-20% sucrose gradient,
fractions of equal volume were collected from the top of the gradient (1
 top and 14 bottom), and aliquots were either precipitated with TCA
for immunoblotting with anti-E2 or anti-p24 (8 or 12% polyacrylamide
gels, respectively) (A) or assayed for infection of Hep3B cells (B). Frac-
tions were incubated either with anti-E2 (11/20; ) or an irrelevant MAb
(10/76b;) for 1 h at 37°C, prior to infection. The migration of molecular
mass markers is indicated (in kilodaltons). RLU, relative light units.
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the loading zone and in the top-most gradient fraction. In
contrast, the majority of p24 sedimented, consistent with its
incorporation into particles released into the medium, with
only a small amount of p24 detectable in the top fraction of the
gradient. Similar results were obtained if the pseudotype virus
stocks were stored at 4°C, 80°C, or analyzed immediately
after harvesting. The same fractions were analyzed for infec-
tivity (Fig. 1B). Since the majority of E2 protein failed to
sediment, to confirm that particle infectivity was HCV gp de-
pendent, all fractions were preincubated with MAb 11/20 spe-
cific for HCV E2 or an irrelevant control MAb, 10/76b. Infec-
tivity for Hep3B cells cosedimented with the p24-containing
gradient fractions and was specifically inhibited by 11/20 (Fig.
1B).
Since the majority of the E2 released from HIV-HCV
pseudotype-producing cells was not associated with infectivity,
it was necessary to remove the nonsedimenting E2 to charac-
terize the gp’s incorporated into infectious particles. Since the
nonsedimenting E2 barely entered the sucrose gradient, this
material could be soluble or of low density. We therefore
assessed whether pelleting the virus through a 20% sucrose
cushion could remove the nonsedimenting species. After pel-
leting, the virus was resuspended in PBS and analyzed by
sedimentation on a 7-to-47% sucrose gradient (Fig. 2). As
previously shown, the majority of E2 in the medium failed to
sediment along the gradient, though a sedimenting species
could be detected upon overexposure of the immunoblot (Fig.
2, upper left panel). Pelleting through the cushion allowed the
removal of the nonsedimenting E2 and concentrated a sedi-
menting species (Fig. 2, upper right panel). A fraction of the
total p24 was observed in the top-most fraction, even after
pelleting through the cushion, possibly representing soluble
p24 that was released from virions disrupted during resuspen-
sion. The E2 protein that sedimented on the gradient migrated
as a diffuse smear with several distinct forms (60, 70, and 90
kDa). Cosedimentation of p24 and E2 was not complete, with
the peak of E2 in fraction 10 and p24 most abundant in frac-
tions 10 and 11.
To assess whether the nonsedimenting E2 species affected
infection by HIV-HCV particles, the top fraction of a 5-to-20%
sucrose gradient, run in parallel to that depicted in Fig. 1, was
added to an infectivity assay using pseudotype particles puri-
fied by pelleting through a sucrose cushion. No infectivity was
associated with this gradient fraction, and its addition had no
effect on the infection by pelleted virus (data not shown). The
nature of this nonsedimenting E2 species remains obscure, but
since it was separable from, and did not affect the infectivity of,
HIV-HCV pseudotype particles, it has not been characterized
further.
Characterization of incorporated E1E2 gp’s. Multiple virus-
and plasmid-based expression systems have been used to dem-
onstrate the localization of HCV E1 and E2 to the ER. Con-
sistent with this location, their N-linked glycans are sensitive to
digestion by endo-H. To assess the glycosylation status of the
incorporated HCV gp’s, pseudotype particles were generated
using an E1E2 expression plasmid, pelleted through a sucrose
FIG. 2. Nonsedimenting E2 is removed by pelleting through a sucrose cushion. HIV-HCV pseudotype particles, either in cell culture medium
(supernatant) or purified by pelleting through a sucrose cushion (pellet), were sedimented upon 7-to-47% sucrose gradients. Fractions were
collected from the top of the gradient (1  top, 14  bottom), precipitated with TCA, and analyzed by immunoblotting with anti-E2 or anti-p24
(8 or 12% polyacrylamide gels, respectively). The migration of molecular mass markers is indicated (in kilodaltons).
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cushion, denatured, and either mock treated or digested with
endo-H or N-glycosidase F. Similar digestions were performed
on transfected cell lysates. E1 and E2 were analyzed by SDS-
PAGE and immunoblotting (Fig. 3).
E1 in cell lysates appeared as a major band, migrating at
27 kDa, with further species migrating at 24 and 20 kDa. The
27-kDa protein probably represents a fully glycosylated E1
species (four glycans added), with the 24-kDa protein partially
glycosylated (three glycans added). The 20-kDa species may
represent a partially deleted form of E1 resulting from excision
of a cryptic intron (14). All of the E1 species in the cell lysate
were sensitive to endo-H, the majority comigrating with the
17-kDa N-glycosidase F-deglycosylated species after digestion.
An E1-related species, migrating at 5 kDa, likely represents
the intron-excised E1 after deglycosylation. Following N-gly-
cosidase F digestion, the signal for both E1 and E2 by immu-
noblotting was reduced, possibly due to reduced recognition of
the deglycosylated form by the MAbs used for immunoblot-
ting. E1 incorporated into the HIV-HCV particles migrated
more slowly than that detected in the cell lysate, with species
migrating at 33, 31, and 25 kDa. Each of these species was, at
least partially, sensitive to endo-H digestion. Following
endo-H treatment, the 17-kDa fully deglycosylated form
(comigrating with N-glycosidase F-treated E1) was detected,
along with a doublet of bands at 21 and 19 kDa. These bands
may represent E1 with two and one endo-H-resistant glycans
added. The minor E1-related product migrating at 5 kDa,
corresponding to the intron-excised E1 after deglycosylation,
was also incorporated into pseudotype particles (apparent
upon longer exposures) (data not shown). E2 in the cell lysate
was sensitive to digestion with endo-H. Doublets of bands were
visible after both endo-H and N-glycosidase F digestion. These
may be the result of a proteolytic cleavage or the presence of
a glycan resistant to digestion with both endo-H and N-glyco-
sidase F (the latter will not cleave oligosaccharides containing
1-3-linked core fucose). In contrast to the cell-associated
form of E2 and the particle-incorporated E1, the majority of
incorporated E2 was completely resistant to endo-H.
Disulfide-linked aggregates have been suggested to result
from a nonproductive folding pathway for E1 and E2, while
noncovalently linked E1E2 heterodimers are thought to be a
prebudding form of the HCV gp’s. To determine if disulfide-
linked aggregates were incorporated into HIV-HCV pseudo-
type particles, viruses were pelleted through a sucrose cushion
and separated by SDS-PAGE under reducing or nonreducing
conditions, and E1 or E2 was detected by immunoblotting (Fig.
4).
Under nonreducing conditions, incorporated E1 and E2
were detected both as slowly migrating (200 kDa) and more
rapidly migrating, nonaggregated species. These slowly migrat-
ing species were absent after reduction, indicating their stabi-
lization by disulfide bonds. These data are consistent with the
incorporation of both disulfide-linked aggregates and nonag-
gregated E1 and E2 into HIV-HCV pseudotype particles. Un-
der nonreducing conditions, nonaggregated E2 migrated as a
doublet, in contrast to the reduced E2, which migrated as three
bands within a diffuse smear. This difference in migration in-
dicated that intramolecular disulfide bonds contribute to the
FIG. 3. Endoglycosidase sensitivity of cell-associated and pseudotype-incorporated gp’s. 293T cells were transfected to generate HIV-HCV
pseudotype particles with plasmids expressing either E1E2 or E1E2p7. Cell lysates or cushion-pelleted particles were denatured prior to mock
digestion () or digestion with endo-H (H) or N-glycosidase-F (F), applied to a reducing SDS-PAGE, and immunoblotted with anti-E1 or anti-E2
antibodies (12 or 10% polyacrylamide gels, respectively). The migration of molecular mass markers is indicated (in kilodaltons).
FIG. 4. Disulfide-linked aggregates of both E1 and E2 are incor-
porated into pseudotype particles. HIV-HCV pseudotype particles
were purified by pelleting through a sucrose cushion before analysis by
reducing (R) or nonreducing (NR) SDS-PAGE and immunoblotting
with anti-E1 or anti-E2 antibodies (12 or 8% polyacrylamide gels,
respectively). The migration of molecular mass markers is indicated (in
kilodaltons).
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secondary structure of the pseudotype particle-incorporated,
nonaggregated E2.
In summary, these data suggest that the pseudotype particle-
associated E1 and E2 passed through the Golgi apparatus,
consistent with retroviral budding from the plasma membrane.
However, the incorporated HCV gp’s were heterogeneous in
nature, consisting of disulfide-linked aggregates and nonaggre-
gated species, with diverse N-linked glycans.
Effect of flanking polyprotein sequences on pseudotype in-
fectivity. Recent studies have generated HIV-HCV pseudo-
types using plasmid expression constructs encoding E1E2.
During virus infection, however, the gp’s are expressed as part
of the HCV polyprotein, flanked by the Core and p7 proteins.
Indeed, the p7 protein is often observed in the context of
E2-p7, a relatively stable protein that may have a function
distinct from that of E2. The recently demonstrated ion chan-
nel activity of p7 (18, 28) is reminiscent of the M2 protein of
influenza virus, which acts to protect the hemagglutinin protein
from the acidic environment of the Golgi during transport to
the cell surface (26, 33). Since HCV gp-mediated entry re-
quires, like influenza virus, a low-pH step, we hypothesized
that p7 might play a similar role to M2 and, hence, coexpres-
sion of p7 with E1E2 may enhance pseudotype particle infec-
tivity.
To examine the effect of p7 upon E1E2 function, we gener-
ated pseudotype particles by expressing E1E2p7. Since E2 and
E2-p7 comigrate on SDS-PAGE, deglycosylation is necessary
to resolve these two species (21). As seen for E1E2-bearing
particles, when E1E2p7 was used as the expression construct, a
doublet of E2-related bands was detected after both endo-H
and N-glycosidase F treatments (Fig. 3). Comparison of the
deglycosylated E2 species generated from plasmids expressing
E1E2 and E1E2p7 showed that E2 generated in the presence
of p7 migrated more slowly. This observation is consistent with
an inefficient cleavage at the E2-p7 junction and expression
and incorporation of an E2-p7 species into pseudotype parti-
cles. Some cleavage at the E2-p7 site was detectable, especially
after endo-H treatment of the cell lysate, where a band comi-
grating with endo-H-treated E2 from the E1E2 plasmid was
visible. Migration of E1 was unaffected by the presence of p7 in
the construct (data not shown).
To compare the infectivity of particles generated from cells
expressing E1E2 or E1E2p7, viruses were pelleted through a
sucrose cushion and assayed for p24 antigen. Quantification of
the particle-associated fraction allowed normalization of par-
ticle numbers and, hence, the evaluation of differences in in-
corporation of E1 and E2. Samples containing equivalent par-
ticulate p24 were analyzed by immunoblotting, and the level of
incorporated E1 and E2 was found to be reduced3-fold upon
p7 coexpression (Fig. 5). Infection of Hep3B cells with equal
amounts of pseudotype particles (based on particulate p24
content) showed comparable levels of infectivity (within a
threefold difference) (Fig. 5B). Similar results were seen when
Huh7.5 cells were used to assay infectivity (data not shown).
These data suggest that E2-p7 is incorporated into pseudotype
particles, and its presence does not modify the particle infec-
tivity.
The Core protein has been shown to interact with E1 (23)
and might conceivably be incorporated into pseudotype parti-
cles. In addition, while the mechanisms are unknown, se-
quences C terminal of the structural proteins are required for
the production of infectious flavivirus particles (1, 20). To test
the effect of Core and NS2 coexpression on pseudotype infec-
tivity, plasmids encoding Core-E1E2p7, E1E2p7NS2, and
Core-E1E2p7NS2 were used to generate pseudotype particles.
Expression of the gp’s from these vectors was reduced com-
FIG. 5. Analysis of pseudotype particles generated using the E1E2p7 expression construct. (A) Incorporation of HCV gp’s, normalized to
particulate p24. Immunoblotting was performed with anti-p24, anti-E1, or anti-E2 antibodies (12, 12, or 8% polyacrylamide gels, respectively). The
migration of molecular mass markers is indicated (in kilodaltons). (B) Infectivity of pseudotypes generated using E1E2 or E1E2p7 for Hep3B cells.
Hep3B cells were infected with transfected cell medium containing 1.2 ng of particulate p24, and 72 h postinfection cells were lysed and assayed
for luciferase activity. This is a representative of three experiments, with comparable data observed. Values are the means of triplicate wells, with
standard deviations indicated. RLU, relative light units.
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pared to that of the E1E2 and E1E2p7 constructs; hence, the
amount of E1 and E2 incorporated into pseudotype particles
was reduced (data not shown). When the infectivity of these
particles was assayed, the reduced levels of incorporation were
reflected in lower levels of luciferase activity.
During analysis of the E1 and E2 present within cell lysates
and particles, an approximately 100-kDa protein species was
detectable when E1E2, and more so when E1E2p7, was ex-
pressed and immunoblots were overexposed (Fig. 6). This spe-
cies was most apparent when blots were probed for the pres-
ence of E1; however, a comigrating band was observed when
probed with anti-E2 MAbs, migrating just above the diffuse E2
bands (data not shown). This species could be detected when
the MAbs were used individually. This protein was not detect-
able, however, upon nonreducing SDS-PAGE, suggesting that
it is a component of the high-molecular-mass, disulfide-linked
complex (Fig. 6, middle panel). After deglycosylation with
endo-H, this band was missing and a faster-migrating band
became apparent, indicating that the species was sensitive to
endo-H digestion (Fig. 6, right panel). This band may repre-
sent an E1E2 form that is resistant to SDS treatment or an
uncleaved E1E2 species, demonstrating a further level of het-
erogeneity within the incorporated gp’s.
DISCUSSION
The HCV gp’s E1 and E2 have been reported to associate in
two ways: covalently linked via disulfide bonds in high-molec-
ular-weight aggregates, or noncovalently in a heterodimeric
complex (9, 12, 13). In most expression systems, E1 and E2
localize to the ER, retaining endo-H-sensitive N-linked glycans
characteristic of the early compartments of the secretory trans-
port system. Due to the lack of an efficient cell culture system
for the propagation of HCV, there is a paucity of information
regarding the native forms of E1 and E2 present in virions.
Such information would help our understanding of the mech-
anisms of virus-cell attachment and membrane fusion and may
guide the development of vaccines to generate immunity
against functional forms of the HCV gp complex. The recent
development of retroviral particles pseudotyped with the HCV
gp’s (2, 10, 19) represents an opportunity to study the func-
tional E1E2 complex.
Surprisingly, the majority of E2 released from 293T cells did
not cosediment with infectious pseudotype particles. The re-
lease of this nonsedimenting material may be related to the cell
surface expression of E2 in the transfected 293T cells. The
length of the E1 and E2 transmembrane domains may be
better suited to spanning the ER membrane, rather than the
plasma membrane, leading to an unstable complex when ex-
pressed at the cell surface. A secreted form of E2 was detected
when E2 was expressed alone and was attributed to a reduced
stability in the membrane in the absence of E1 (6). An alter-
native explanation is that the nonsedimenting E2 is incorpo-
rated in particles associated with a low-density component that
prevents them from entering a sucrose gradient. A nonsedi-
menting E2 species could be detected when E1E2 of genotypes
1b and 2a were expressed and when E1E2 was expressed in the
absence of HIV proteins (data not shown). Since the nonsedi-
menting E2 was not infectious and failed to affect infection by
pseudotype particles, its biological relevance is unclear. Pellet-
ing pseudotype particles through a sucrose cushion allowed us
to separate the nonsedimenting E2 species from the infectious
particles and to characterize the gp’s incorporated into infec-
tious particles. Analysis of gradient fractions for E2 and p24,
using gradients of various sucrose concentrations, failed to
show a complete cosedimentation, with the peak of p24 anti-
gen always further down the gradient than E2 (Fig. 2). This
suggests that not all of the particles contain E2 and that HCV
gp’s may preferentially incorporate into slower-sedimenting
particles.
Analysis of the glycosylation status of E1 and E2 incorpo-
rated into pseudotype particles indicated that the majority of
E2 was endo-H resistant. In contrast, when E1 was treated with
endo-H, a fully deglycosylated form was observed (comigrating
with N-glycosidase-F-treated E1), as well as 21- and 19-kDa
species. These latter two forms probably correspond to the
addition of two and one endo-H-resistant glycans, respectively.
These observations are consistent with the budding of HIV-
HCV particles through the plasma membrane, as previously
proposed (19). After digestion with N-glycosidase F, doublets
of E2-related bands were observed. We cannot rule out the
possibility that the N-glycosidase F digestion reactions were
not all complete, although E1 in the same lysates was com-
pletely deglycosylated under these conditions. An alternative
explanation is that E2 undergoes a proteolytic cleavage or that
the doublet may be derived by alternative splicing due to the
presence of cryptic splice sites that are utilized during the
nuclear expression of the gp’s. Dumonceaux and colleagues
recently reported the expression of an E1 species containing an
in-frame deletion due to excision of an intron sequence during
nuclear transcription in a plasmid-based expression system
(14). We were able to detect a 20-kDa E1 species in cell lysates
which may correspond to the intron-excised E1 (Fig. 3). After
FIG. 6. A 100-kDa species is present in cell lysates and pseudotype
particles. Particles were generated using E1E2 or E1E2p7 expression
constructs. Cell lysates were separated under reducing (left panel) or
nonreducing (middle panel) conditions on 12% polyacrylamide gels,
followed by immunoblotting with anti-E1. Particles were purified by
pelleting through a sucrose cushion and then denatured and either
mock treated () or treated with endo-H (H). Samples were separated
by reducing SDS-PAGE and immunoblotted with anti-E1. The migra-
tion of molecular mass markers is indicated (in kilodaltons).
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digestion with endo-H, the deleted E1 migrated at5 kDa and
was incorporated into the pseudotype particles. Since HCV is
not expected to be transcribed in the nucleus and the splice
acceptor site is not conserved among other HCV strains (P.
Balfe, personal communication), the biological relevance of
this E1 species is questionable.
Comparison of reduced and nonreduced samples indicated
that incorporated E1 and E2 were in both high-molecular-mass
forms dependent upon the integrity of disulfide bonds and also
in non-disulfide-linked species (Fig. 4). The high-molecular-
weight forms likely represent the disulfide-linked aggregates
that have been observed in other expression systems and that
have been suggested to result from a nonproductive folding
pathway (4). Such complexes were found in particles purified
from a chronically HCV-infected patient (29), suggesting that
they may represent a natural form of E1 and E2 in the virion.
In this latter study, however, the infectivity of the recovered
particles was not demonstrated.
The p7 protein has recently been demonstrated to possess
ion channel activity (18, 28). This activity is reminiscent of the
M2 protein of fowl plague virus, which can act to protect the
viral hemagglutinin protein from the acidic environment of the
trans-Golgi network during its transportation through the se-
cretory pathway, avoiding the low-pH-induced conformational
changes that occur during influenza virus entry (26, 33). Since
HCV gp-mediated entry is, like influenza virus, acid dependent
and the pseudotype-incorporated E1 and E2 proteins pass
through the Golgi (as indicated by the endo-H resistance of
E1- and E2-associated glycans), we hypothesized that p7 might
play a role similar to that of M2 in increasing the Golgi pH.
Coexpression of p7 with E1E2 might therefore give rise to
pseudotype particles of greater infectivity. This was not the
case, however, as particles generated with E1E2 or E1E2p7
were of similar infectivity. It is possible that an ion channel
activity of p7 has a role to play in the biogenesis of the au-
thentic HCV particle. An E1- and E2-related protein of 100
kDa was detected in both cell lysates and pseudotype particles
and could be visualized with antibodies specific for both E1
and E2. This species was more abundant when E1E2p7 was
expressed, suggesting that its formation may be favored by the
presence of p7. This band may represent an SDS-resistant
heterodimer of E1E2, an uncleaved E1E2 species, or an as-
sembly intermediate for the HCV gp’s.
Thus, the gp’s incorporated into HIV-HCV pseudotype par-
ticles exhibit heterogeneity with regard to their glycosylation
pattern and disulfide linkages. Initially, we intended to utilize
the HIV-HCV pseudotype particles to assess the antigenicity
of the functional E1 and E2 gp’s at neutral and low pH; how-
ever, the diversity of incorporated gp’s makes these assays
difficult to interpret. Such heterogeneity is perhaps unsurpris-
ing, given the incorporation of both functional and nonfunc-
tional HIV gp120-41 molecules into HIV particles (31). It was
speculated that nonfunctional envelope gp’s represent an im-
munodominant antigen during HIV infection, biasing the hu-
moral immune response towards antibodies that have minimal
reactivity to functional gp’s and, hence, have poor neutralizing
activity. It remains to be determined whether nonfunctional
forms of the HCV gp’s are incorporated into pseudotypes or
virions in vivo and, indeed, which form of the HCV gp’s is
responsible for mediating pseudotype infectivity.
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